Chimeric antigen receptor T-cell therapy for multiple myeloma

Abstract

Chimeric antigen receptor (CAR) T cell therapy, an immunotherapy using gene-modified T cells, has recently made a big success. CAR T cells targeting CD19 is highly effective against B cell malignancies. Next good target for CAR T therapy is multiple myeloma. B cell maturation antigen has been proved to be a good target for CAR T cell therapy in early-phase clinical trials. We are also developing CAR T cells targeting a protein conformation that is preferentially detected in myeloma cells. In this review, I will summarize the state of art in the field of CAR T cell therapy against myeloma, and also present our effort to develop a new CAR T cell therapy.